

PIPER RUDNICK LLP

1200 NINETEENTH STREET, NW WASHINGTON, DC 20036-2412 TELEPHONE: 202-861-3900

FACSIMILE: 202-223-2085

DOCKET NO.: 5398-027-27 CONT

ASSISTANT COMMISSIONER FOR PATENTS PO BOX 1450 ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/697,720

Applicant(s): Stanley N. COHEN, et al.

Filing Date: October 29, 2003

For: MAMMALIAN TUMOR SUSCEPTIBILITY GENES AND THEIR

USES

Group Art Unit: 1642 Examiner: Unassigned

SIR:

Attached hereto for filing are the following papers:

Fee Transmittal
Request for Extension of Time (4 months)
Notice to Comply (Return Copy)
Response to Notice to Comply and Preliminary Amendment
Statement Under 37 C.F.R. § 1.821-1.825 (1 page, executed)
Substitute Sequence Listing (paper copy, 9 pages)
Computer Readable Sequence Listing (diskette)

Our check in the amount of \$ 740.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP

Vidael Th

Steven B. Kelber

Attorney of Record

Registration No.: 30,073

Michael Ye

Registration No.: 47,195



FEE TRANSMITTAL

 Docket No.
 5398-027-27 CONT

 Serial No.
 10/697,720

 Filing Date
 October 29, 2003

 Inventor(s)
 Stanley N. COHEN, et al.

 Group Art Unit
 1642

											Group Art	Unit	16	42		
									40.0	Examiner	xaminer Unassigned					
					•••				-	•	1				TO 1. () . ()	
Applicant claims small entity status.								FEE CALCULATION (continued)								
Charge any <u>UNDERPAYMENT</u> or credit any <u>OVERPAYMENT</u> in the indicated fees to Deposit Account No. 50-1442.								3. ADI	3. ADDITIONAL FEES							
_	Charge the indicated fees to Deposit Account No. 50-1442.										Large	Large Entity			Fee Description	
_										Fee					Far Daid	
2.	2. Check enclosed.											Fee (\$)	Fee Code	Fee (\$)		Fee Paid
	FEE CALCULATION											130	2051	65	Surcharge-late filing fee or oath	
1. BASIC FILING FEE									1052	50	2052	25	Surcharge-late provisional filing fee or cover sheet			
Large Entity Small En				tity	Fee Description				1053	130	1053	130	Non-English Specification			
Fee Code	Fee (\$)	Fee Code		Fee (\$)						Fee Paid	1251	110	2251	55	1-mo. ext. of time	
1001	770	2001		385	Utility filing fee					1252	420	2252	210	2-mo. ext. of time		
1002	340	2002	170		Design filing fee					1253	950	2253	475	3-mo. ext. of time		
1003	520	2003	260		Plant filing fee						1254	1480	2254	740	4-mo. ext. of time	740.00
1004	770	2004	385		Reissue filing fee						1255	2010	2255	1005	5-mo. ext. of time	
1005	160	2005	80		Provisional filing fee						1401	330	2401	165	Notice of Appeal	
SUBTOTAL (1) \$0.00									1402	330	2402	165	Appeal Brief			
2. EXTRA CLÂIM FEES							1403	290	2403	145	Request for Oral Hearing					
tot. cla	aims		-	20*	=	0	x	\$9		0	1501	1330	2501	665	Utility/Reissue Issue Fee	
ind. cl	aims		-	3*	=	0	х	\$43	=	0	1502	480	2502	240	Design Issue Fee	<u> </u>
	Multip	le Dependent Claims \$145 = 1504 300 1504 300		Publication Fee	,											
Large	Large Entity Small En				Entity Fee Description							3	8001	3	Advance Copy of Patent	
Fee Code	Fee (\$)	Fee Code	Fee (\$)								1460	130	1460	130	Petitions to the Commissioner	
1202	18	2202		9	Claims in excess of 20						1806	180	1806	180	IDS Submission	
1201	86	2201		43	Independent claims in excess of			of 3		8021	40	8021	40	Assignment recordation		
1203	290	2203		145	Multiple dependent claim, if not paid				ot paid	1	1801	770	2801	385	For Filing RCE	
1204	84	2204		43	*Reissue independent claims over original patent					1814	110	2814	55	Terminal Disclaimer		
1205	18	2205		9	*Reissue claims in excess of 20 and over original patent						OTHER (OTHER (indicate below):				
		·····				SUE	зто	TAL (2)		\$0.00						
* or nun	or number previously paid, if greater; For Reissues, see above						SUBTOTAL (3)				\$740.00					

Name	Steven B. Kelber	Registration No.	30,073		
Signature	min of	Date 6-30-04	Telephone 202-861-3900		
Name	Michael Ye	Registration No.	47,195		



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PC. Dox 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/697,720

10/29/2003

Stanley N. Cohen

. S93-160 CON2

Bertram I. Rowland, Esq. Lumen Intellectual Property Services, Inc. 2nd Floor 2345 Yale Street Palo Alto, CA 94306 JUN 2 9 2004 35

CONFIRMATION NO. 3761
FORMALITIES LETTER

OC000000011585019

Date Mailed: 12/30/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE